Related Experiment Video
Updated: Jun 6, 2025

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
Published on: August 6, 2021
TGF-β1-induced apoptosis in retinal endothelial cells is implicated in retinal vein occlusion
Fengyu Chen1, Qi Wang1, Yujin Li1
1Department of Hematology, The First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Hematologic Disease, Yunnan Province Clinical Center for Hematologic Disease, Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, Kunming, Yunnan, China; Department of Hematology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.
Abstract:
Retinal vein occlusion (RVO) is a serious vascular condition that impairs vision due to retinal endothelial cell injury and apoptosis. This study aimed to identify key molecular pathways and therapeutic targets involved in RVO pathogenesis. Transcriptomic analysis of the retinal tissues from a mouse RVO model was performed to identify differentially expressed genes and co-expression modules associated with RVO. Protein-protein interaction network analysis pinpointed putative hub genes. In vitro experiments using human retinal microvascular endothelial cells (HRMECs) validated the involvement of identified genes/pathways in apoptosis induced by oxygen-glucose deprivation/reperfusion (OGD/R) and UV exposure. Gene expression was assessed by RT-qPCR, while protein levels and phosphorylation were measured by ELISA and Western blotting. Apoptosis was evaluated using flow cytometry, and reactive oxygen species (ROS) were quantified using a fluorescence-based assay. A total of 392 genes were identified as putatively involved in RVO-associated apoptosis, enriched in MAPK, TGF-β and other signaling pathways. Among top hub genes, TGF-β1 emerged as a central regulator whose expression and signaling (pSmad2/3) increased after OGD/R induction or UV exposure in HRMECs. TGF-β1-induced HRMEC apoptosis was mediated by p38/JNK activation. Similar effects were observed for OGD/R and UV triggering TGF-β1-dependent p38/JNK signaling and apoptosis. Pharmacological inhibition of TGF-β signaling attenuated the apoptotic and oxidative stress responses induced by OGD/R and UV exposure. This study elucidates TGF-β1 as a crucial mediator of retinal endothelial injury through p38/JNK-induced apoptosis, suggesting TGF-β1 pathway inhibition as a potential therapeutic strategy for RVO.
Insights
Transforming retinal vein occlusion (RVO) treatment, this study reveals transforming growth factor-beta 1 (TGF-β1) as a key driver of retinal endothelial cell apoptosis. Inhibiting the TGF-β1 pathway offers a promising therapeutic strategy for RVO.
Area of Science:
- Ophthalmology
- Vascular Biology
- Molecular Medicine
Background:
- Retinal vein occlusion (RVO) causes vision loss via retinal endothelial cell injury and apoptosis.
- Identifying molecular pathways is crucial for developing effective RVO therapies.
Purpose of the Study:
- To identify key molecular pathways and therapeutic targets in RVO pathogenesis.
- To investigate the role of TGF-β1 in RVO-induced endothelial cell apoptosis.
Main Methods:
- Transcriptomic analysis in a mouse RVO model.
- In vitro studies using human retinal microvascular endothelial cells (HRMECs) subjected to oxygen-glucose deprivation/reperfusion (OGD/R) and UV exposure.
- Assays for gene expression, protein levels, apoptosis, and reactive oxygen species (ROS).
Main Results:
- 392 differentially expressed genes were identified, enriched in MAPK and TGF-β signaling pathways.
- TGF-β1 expression and signaling (pSmad2/3) increased in HRMECs after OGD/R or UV exposure.
- TGF-β1 mediated apoptosis via p38/JNK activation, and its inhibition reduced apoptosis and oxidative stress.
Conclusions:
- TGF-β1 is a critical mediator of retinal endothelial injury in RVO through p38/JNK-induced apoptosis.
- Inhibiting the TGF-β1 pathway presents a potential therapeutic strategy for RVO.
- This research provides novel insights into RVO pathogenesis and treatment targets.

